These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 35091289)
1. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold. Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
3. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors. Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005 [TBL] [Abstract][Full Text] [Related]
4. Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. Hassan A; Badr M; Hassan HA; Abdelhamid D; Abuo-Rahma GEA Bioorg Med Chem; 2021 Jun; 40():116168. PubMed ID: 33962153 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
6. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
7. Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study. Salem MG; El-Maaty DMA; El-Deen YIM; Elesawy BH; Askary AE; Saleh A; Saied EM; Behery ME Molecules; 2022 Jul; 27(15):. PubMed ID: 35956848 [TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors. Zengin M; Unsal Tan O; Arafa RK; Balkan A Bioorg Chem; 2022 Apr; 121():105696. PubMed ID: 35217379 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053 [TBL] [Abstract][Full Text] [Related]
10. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477 [TBL] [Abstract][Full Text] [Related]
11. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081 [TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of 3-substituted quinazoline-2,4(1 Hassan A; Mubarak FAF; Shehadi IA; Mosallam AM; Temairk H; Badr M; Abdelmonsef AH J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2189578. PubMed ID: 36919632 [TBL] [Abstract][Full Text] [Related]
13. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720 [TBL] [Abstract][Full Text] [Related]
14. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition. El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185 [TBL] [Abstract][Full Text] [Related]